Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
866 studies found for:    "Lymphoma large-cell"
Show Display Options
Rank Status Study
1 Completed Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Condition: Large Cell Lymphoma
Intervention: Drug: SGN-30
2 Completed Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large-Cell Lymphoma
Intervention: Drug: SGN-30 (anti-CD30 mAb)
3 Recruiting A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Condition: Systemic Anaplastic Large-Cell Lymphoma
Intervention: Drug: crizotinib
4 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
5 Recruiting Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
6 Terminated
Has Results
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma
Interventions: Biological: monoclonal antibody SGN-30;   Drug: therapeutic hydrocortisone;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide;   Drug: methotrexate;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Not yet recruiting Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Systemic Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ceritinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
8 Recruiting Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Condition: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Intervention: Drug: Brentuximab vedotin (recombinant)
9 Recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine;   Drug: Neulasta
10 Completed Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Intervention: Biological: XmAb2513
11 Active, not recruiting Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
12 Completed
Has Results
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: Brentuximab vedotin and rifampicin
13 Recruiting Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Conditions: Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate
14 Completed
Has Results
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: tanespimycin
15 Recruiting Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
16 Withdrawn Denileukine Diftitox for Relapsed ALCL
Condition: Anaplastic Large-Cell Lymphoma
Interventions: Drug: Denileukin Diftitox;   Drug: Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
17 Recruiting Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Condition: ALK+ Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Imatinib
18 Completed Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
Condition: Lymphoma
Interventions: Genetic: microarray analysis;   Genetic: protein expression analysis;   Genetic: western blotting;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry
19 Completed
Has Results
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
20 Completed Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.